Endocrine Abstracts

Background: DNA methylation analysis has been proven useful biomarker in patients with colon (1-3), breast (4), and lung cancer (5). However, the clinical utility of this method in neuroendocrine neoplasms (NENs) is limited. Our research group has previously worked on the role of circulating cell-free tumour DNA (ctDNA) in neuroendocrine tumours (NETs) and thyroid cancers. Preliminary findings showed that this is a potentially useful clinical tool (6). We are expanding our res...